XCancer

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Description:

The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

Early Phase 1

Contacts:

Mark Dunphy, DO (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01269593 - Click here to see study on

ClinicalTrials.gov

PUH71

Isotope(s):
Target(s):
  • HSP90
Ligand Class: Small Molecules
Inclusion
  • This does not apply to patients with myeloproliferative neoplasm. The presence of active myeloproliferative neoplasm will be determined by applicable disease specific diagnostic criteria and patient assessment by the patient's oncologist and trial investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood counts, etc).
  • Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol.
  • Age between 18-90
  • * Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology)
  • Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential
Exclusion
  • AST/ALT \>2.5 x ULN
  • Known hyperthyroidismHepatic:
  • * Previous allergic reaction to contrast medium.
  • Bilirubin \> 1.5 x institutional upper limit of normal (ULN)
  • Hypersensitivity to iodide products.